.jpg?format=webp&width=780)
The article discusses the results of the ANNEXA-4 study, which evaluated the use of Andexanet alfa, a modified recombinant inactive factor Xa (FXa), to reverse the effects of FXa inhibitors in patients with major acute bleeding. The study found that treatment with Andexanet alfa reduced anti-FXa activity and was associated with good or excellent hemostatic efficacy in 80% of patients. The study also assessed the safety of Andexanet alfa and found that thrombotic events occurred in 10% of patients, but no thrombotic episodes occurred after the oral anticoagulation restart. The study suggests that Andexanet alfa may be an effective treatment for major bleeding associated with using FXa inhibitors.
Like
Save
Share